Korean Journal of Gastrointestinal Endoscopy 1991;11(2): 279-283.
염산 베넥세이트 베타덱스 ( 울굿ⓡ ) 의 위궤양에 대한 치료효과 ( The Efficacy of Benexate HCI Betadex in Treatment of Gastric Ulcer )
양진모, 채현석, 이승헌, 최명규, 한석원, 최상욱, 정인식, 정규원, 선희식, 김부성 (Jin Mo Yang, Hyun Seok Chae, Seung Hun Lee, Myung Cyu Choi, Seok Won Han, Sang Wook Choi, In Sik Chung, Kyu Won Chung, Hee Sik Sun and Boo Sung Kim)
Abstract
Benexate HCl betadex (Ulgut) is a newly introduced antiulcer agent which stimulates production of mucus and enhanced mucosal blood flow on, gastric mucosa. This agent is known to have efficacy in treatment of peptic ulcer. This study was designed to evaluate the efficacy and safety of Benexate HCl betadex in treatment of gastric ulcer. Thirty-three patients with endoscopically diagnosed gastric ulcer were treated with Benexate HCl betadex 400 mg twice daily per os for 4 ar 8 week. Among them 3 patients were excluded due to missed during follow-up in two patients and one with gastric cancer, Every patients were assessed clinically and endoscopically before treatment, at 1 week, 2 weeks, 4 weeks, 6 weeks and 8 weeks after treatment. The result were as follows. 1) The rate of completely healing of gastric ulcer was 36.7% at 4 weeks and 76.7% at 8 weeks after the treatment. 2) Clinical symptoms(epigastric pain) disappeared in 96.7% of patients with gastric ulcer at 1 week. 3) Three patients developed side effects of drug including constipation, skin rash and liver function abnormality, respectively. These results demonstrated that Benexate HCl betadex 400 mg twice daily p.o. could be effective and safe in treatment of gastric ulcer patients.
PDF Links
Full text via DOI 
Download Citation 
